Medicare AdvantageCoverageMedium impact
MA08.136g, Dostarlimab-gxly (Jemperli)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated the medical necessity criteria for dostarlimab-gxly (Jemperli), a cancer immunotherapy drug. This change affects the requirements for coverage approval of this specialty oncology medication.
Action Required
By June 1, 2026: Billing team must review and update prior authorization requirements for dostarlimab-gxly (Jemperli) prescriptions for Medicare Advantage patients. Contact oncology providers to inform them of updated medical necessity criteria. Review full policy at source URL to understand specific documentation requirements.